Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

AstraZeneca pushes back timeline for MYSTIC phase III lung cancer clinical trial

Based on current predictions, the final analysis of overall survival data from the phase III study is expected in the second-half of the year rather than the first
AstraZeneca pushes back timeline for MYSTIC phase III lung cancer clinical trial
The open-label efficacy assessment was designed to test the combination therapy against the current gold standard chemotherapy for patients with a form of locally-advanced or metastatic non-small cell lung cancer

AstraZeneca PLC (LON:AZN) said the timeline for its closely-followed MYSTIC clinical trial, treating patients with late-stage lung cancer has been pushed back.

Based on current predictions, the final analysis of overall survival data from the phase III study is expected in the second-half of the year rather than the first.

MYSTIC deployed Imfinzi, developed by AZ’s US biotechnology arm MedImmune, in combination with tremelimumab, an antibody treatment also created by the company’s American research arm.

The open-label efficacy assessment was designed to test the combination therapy against the current gold standard chemotherapy for patients with a form of locally-advanced or metastatic non-small cell lung cancer.

The trial is being conducted in 167 centres across 17 countries, including the US, Canada, Europe, and parts of Asia.

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

test tubes in a laboratory
November 06 2017
“We are delighted that RedX has exited administration as a going concern and with a strengthened board and management team that will ensure enhanced oversight and provide relevant industry expertise as well as continuity to the business”
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use